Semaglutide targets one hormone receptor, while tirzepatide targets two, which is why some patients see a different response between the two medications
The metabolic benefits of GLP-1 therapy extend well beyond weight loss, including beta-cell preservation, improved insulin sensitivity, and cardiovascular risk reduction
Khavinson's research showed increased telomere length in human cell cultures and extended lifespan in animal models
Depending on where you live and your insurance coverage, these drugs may cost less than Wegovy
The global GLP-1 market was valued at $52.82 billion in 2025 and is projected to reach $133.92 billion by 2034, growing at 10.9 percent annually
L KA, Faeh D, Stettler R, Ith M, Kreis R, Vermathen P, et al